AstraZeneca PLC’s (AZN) EPS growth ratio for the past five years was -16.70% while Sales growth for the past five years was -5.80%. Jefferies maintained the stock on July 14 with “Underperform” rating.
Advertisement
With its market value over its outstanding shares, AstraZeneca PLC (NYSE:AZN) Drug Manufacturers – Major has a market capitalization valued at Drug Manufacturers – Major. The company most recent volume stood at 11.36 million shares as compared to average volume of 4.44 million shares. Institutional ownership in the company is 10.80% while the short ratio is 5.2. Now shares have been rated as “Buy” from 5 Analysts. The Company’s segment is the business of exploration and mining of precious metals.
Advertisement
A number of other analysts have also recently commented on the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Credit Suisse Group AG restated an “underperform” rating and issued a GBX 4,000 ($51.89) target price on shares of AstraZeneca plc in a report on Wednesday. Lastly, Citigroup downgraded the stock to “Sell” rating in a May 9 report. Berenberg Bank set a GBX 1,785 ($23.15) price objective on GlaxoSmithKline plc and gave the company a “neutral” rating in a research report on Friday, July 8th. The current PEG for AstraZeneca PLC NYSE:AZN is valued at *TBA with a P/S value of 3.08. The highest share price LON:AZN shares have reached in the prior twelve months is 4634 with the lowest being 3680. The company has a market cap of 3.21 billion GBP. GBX 1747 is the highest target while GBX 1 is the lowest. The 20-Day Simple Moving Average is determined at 4.38% that showed a 200-Day Simple Moving Average of 0.46%. Shares are down 11.7% year-to-date as of the close of trading on Monday. The total volume of shares traded was 1764407 which puts the relative volume at 8.01 for the day. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal.
